He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022. The FDA's announcement comes months after drugmaker Novo Nordisk told the agency ...
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Novo Nordisk’s semaglutide weight-loss (Wegovy) and diabetes (Ozempic) drugs are no longer in short supply, U.S. regulators said Feb. 21, 2025, a decision that’s expected to curtail widespread ...
Novo’s semaglutide, sold under the brand names Ozempic for diabetes and Wegovy for obesity, had been on the FDA’s drug shortage list for over two years. During that time, patients flocked to ...
Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...